 Proto-Oncogene Proteins
"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 6 | 12 | | 1996 | 5 | 6 | 11 | | 1997 | 9 | 5 | 14 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 3 | 5 | | 2000 | 14 | 2 | 16 | | 2001 | 6 | 4 | 10 | | 2002 | 14 | 12 | 26 | | 2003 | 6 | 11 | 17 | | 2004 | 13 | 18 | 31 | | 2005 | 7 | 10 | 17 | | 2006 | 9 | 4 | 13 | | 2007 | 4 | 3 | 7 | | 2008 | 8 | 5 | 13 | | 2009 | 11 | 3 | 14 | | 2010 | 7 | 7 | 14 | | 2011 | 11 | 7 | 18 | | 2012 | 9 | 8 | 17 | | 2013 | 15 | 10 | 25 | | 2014 | 10 | 13 | 23 | | 2015 | 7 | 5 | 12 | | 2016 | 8 | 3 | 11 | | 2017 | 5 | 6 | 11 | | 2018 | 12 | 7 | 19 | | 2019 | 6 | 2 | 8 | | 2020 | 5 | 4 | 9 | | 2021 | 6 | 3 | 9 | | 2022 | 0 | 8 | 8 | | 2023 | 1 | 4 | 5 | | 2024 | 2 | 3 | 5 | | 2025 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, ?ucenka A, de Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, K?hn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, D?hner H, Greco C, Kovacsovics T, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 Aug 28; 146(9):1065-1077.
-
Tran AT, Wisniewski EO, Mistriotis P, Stoletov K, Parlani M, Amitrano A, Ifemembi B, Lee SJ, Bera K, Zhang Y, Tuntithavornwat S, Afthinos A, Kiepas A, Agarwal B, Nath S, Jamieson JJ, Zuo Y, Habib D, Wu PH, Martin SS, Gerecht S, Gu L, Lewis JD, Kalab P, Friedl P, Konstantopoulos K. Cytoplasmic anillin and Ect2 promote RhoA/myosin II-dependent confined migration and invasion. Nat Mater. 2025 Sep; 24(9):1476-1488.
-
Saeedi BJ, Carr HE, Higgins PDR, Steiner CA. AXL: A novel therapeutic target in IBD. Adv Pharmacol. 2024; 101:141-157.
-
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan; 43(1):75-84.
-
Becht DC, Mohid SA, Lee JE, Zandian M, Benz C, Biswas S, Sinha VK, Ivarsson Y, Ge K, Zhang Y, Kutateladze TG. MLL4 binds TET3. Structure. 2024 06 06; 32(6):706-714.e3.
-
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 01 11; 390(2):118-131.
-
Chen N, Tyler LC, Le AT, Welsh EA, Fang B, Elliott A, Davies KD, Danhorn T, Riely GJ, Ladanyi M, Haura EB, Doebele RC. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling. Mol Cancer Ther. 2024 Jan 03; 23(1):92-105.
-
Liao Y, Remsing Rix LL, Li X, Fang B, Izumi V, Welsh EA, Monastyrskyi A, Haura EB, Koomen JM, Doebele RC, Rix U. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2. Cell Chem Biol. 2024 Feb 15; 31(2):284-297.e10.
-
Peters TL, Chen N, Tyler LC, Le AT, Dimou A, Doebele RC. Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression. Thorac Cancer. 2023 11; 14(33):3259-3265.
-
Ravindran Menon D, Hammerlindl H, Gimenez G, Hammerlindl S, Zuegner E, Torrano J, Bordag N, Emran AA, Giam M, Denil S, Pavelka N, Tan AC, Sturm RA, Haass NK, Rancati G, Herlyn M, Magnes C, Eccles MR, Fujita M, Schaider H. H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase. Drug Resist Updat. 2023 Nov; 71:100993.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|